Parallel Advisors, LLC Biogen Inc. Transaction History

Parallel Advisors, LLC

  • $3.87 Billion
  • Q2 2024

A detailed history of Parallel Advisors, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 1,982 shares of BIIB stock, worth $344,451. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,982
Previous 1,826 8.54%
Holding current value
$344,451
Previous $393,000 16.79%
% of portfolio
0.01%
Previous 0.01%

Shares

33 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024
BUY
$190.52 - $236.72 $29,721 - $36,928
156 Added 8.54%
1,982 $459,000
Q1 2024

May 06, 2024
SELL
$212.02 - $267.71 $15,901 - $20,078
-75 Reduced 3.95%
1,826 $393,000
Q4 2023

Feb 09, 2024
SELL
$222.59 - $267.94 $7,345 - $8,842
-33 Reduced 1.71%
1,901 $491,000
Q3 2023

May 20, 2024
SELL
$253.3 - $285.89 $25,076 - $28,303
-99 Reduced 4.87%
1,934 $497,000
Q3 2023

Nov 13, 2023
SELL
$253.3 - $285.89 $25,076 - $28,303
-99 Reduced 4.87%
1,934 $497,000
Q2 2023

May 20, 2024
BUY
$275.25 - $318.06 $11,560 - $13,358
42 Added 2.11%
2,033 $579,000
Q2 2023

Aug 04, 2023
BUY
$275.25 - $318.06 $11,560 - $13,358
42 Added 2.11%
2,033 $579,000
Q1 2023

May 20, 2024
BUY
$256.56 - $292.34 $42,332 - $48,236
165 Added 9.04%
1,991 $553,000
Q1 2023

Apr 25, 2023
SELL
$256.56 - $292.34 $14,623 - $16,663
-57 Reduced 2.78%
1,991 $553,000
Q4 2022

Feb 03, 2023
BUY
$252.44 - $306.72 $73,460 - $89,255
291 Added 16.56%
2,048 $567,000
Q3 2022

Nov 10, 2022
SELL
$194.69 - $268.46 $3,115 - $4,295
-16 Reduced 0.9%
1,757 $469,000
Q2 2022

Aug 01, 2022
SELL
$187.54 - $223.02 $14,815 - $17,618
-79 Reduced 4.27%
1,773 $362,000
Q1 2022

Apr 28, 2022
SELL
$193.77 - $244.14 $28,677 - $36,132
-148 Reduced 7.4%
1,852 $391,000
Q4 2021

Jan 20, 2022
SELL
$223.92 - $287.77 $42,992 - $55,251
-192 Reduced 8.76%
2,000 $480,000
Q3 2021

Nov 02, 2021
BUY
$282.99 - $369.05 $6,225 - $8,119
22 Added 1.01%
2,192 $620,000
Q2 2021

Aug 06, 2021
BUY
$259.0 - $414.71 $51,023 - $81,697
197 Added 9.98%
2,170 $751,000
Q1 2021

Apr 23, 2021
SELL
$242.95 - $284.63 $4,373 - $5,123
-18 Reduced 0.9%
1,973 $552,000
Q4 2020

Feb 02, 2021
BUY
$236.26 - $355.63 $34,966 - $52,633
148 Added 8.03%
1,991 $488,000
Q3 2020

Oct 27, 2020
BUY
$264.77 - $305.71 $15,091 - $17,425
57 Added 3.19%
1,843 $523,000
Q2 2020

Jul 16, 2020
SELL
$258.66 - $342.55 $187,528 - $248,348
-725 Reduced 28.87%
1,786 $477,000
Q1 2020

Apr 27, 2020
BUY
$268.85 - $341.04 $223,145 - $283,063
830 Added 49.38%
2,511 $794,000
Q4 2019

Jan 30, 2020
SELL
$220.06 - $304.07 $51,714 - $71,456
-235 Reduced 12.27%
1,681 $499,000
Q3 2019

Nov 01, 2019
BUY
$217.44 - $243.88 $163,080 - $182,910
750 Added 64.32%
1,916 $446,000
Q2 2019

Aug 05, 2019
SELL
$219.29 - $241.72 $45,831 - $50,519
-209 Reduced 15.2%
1,166 $273,000
Q1 2019

May 01, 2019
SELL
$216.71 - $338.96 $21,887 - $34,234
-101 Reduced 6.84%
1,375 $325,000
Q4 2018

Feb 05, 2019
BUY
$278.5 - $352.75 $22,280 - $28,220
80 Added 5.73%
1,476 $443,000
Q3 2018

Nov 01, 2018
BUY
$293.51 - $383.83 $13,794 - $18,040
47 Added 3.48%
1,396 $492,000
Q2 2018

Jul 30, 2018
BUY
$257.52 - $306.91 $56,654 - $67,520
220 Added 19.49%
1,349 $391,000
Q1 2018

May 08, 2018
BUY
$260.13 - $367.91 $19,769 - $27,961
76 Added 7.22%
1,129 $309,000
Q4 2017

Feb 13, 2018
BUY
$307.64 - $344.58 $13,536 - $15,161
44 Added 4.36%
1,053 $335,000
Q3 2017

Nov 15, 2017
BUY
$281.15 - $329.69 $283,680 - $332,657
1,009 New
1,009 $319,000
Q3 2017

Nov 14, 2017
SELL
$281.15 - $329.69 $283,399 - $332,327
-1,008 Closed
0 $0
Q2 2017

Aug 07, 2017
BUY
N/A
1,008
1,008 $292,000

Others Institutions Holding BIIB

# of Institutions
1,018
Shares Held
128M
Call Options Held
1.22M
Put Options Held
1.4M
View Full List

About BIOGEN INC.

BIIB Quotes by TradingView
  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email